---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report. Covers Cost-effectiveness evidence and Budget impact model. 9 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: published economic evidence and company market statements

- The report holds no published cost-effectiveness analysis, health technology assessment, or analyst sales forecast for ersodetug in tumor hyperinsulinism. All economic statements come from the manufacturer.
- The manufacturer's U.S. patient estimates use different measures: approximately 3,000 patients per year as the “immediately addressable incidence market” (Form 10-K), approximately 4,000 patients per year on the same measure (Form 10-Q), approximately 4,500 patients as the “total addressable market” (2024 release, which states that including NICTH would more than double the population), and about 2,500 malignant insulinoma and about 1,500 NICTH patients as a point-in-time prevalence as of October 2026 from the Veeva Compass claims database (October 2026 presentation).
- The October 2026 presentation gives a tumor HI market of about 4,000 patients and a total addressable market of $4 to 5 billion, a combined U.S. opportunity of about 6,000 patients, and a global market opportunity of more than $5 billion.
- Company payer research describes the indications as having low budgetary impact that supports ultra-rare disease pricing, and states likely payer acceptance of weight-based pricing. At a 9 mg/kg maintenance dose and an average adult weight of about 80 kg, the company assumes 9 vials per infusion and 117 vials per year per patient with infusion every four weeks.
- The primary payer in the company's claims data was Medicare for 48.6% of patients, commercial insurance for 43.9%, Medicaid for 5.5%, and other payers for 2.0%.

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-4.1-2"></a>

#### Company estimates of the immediately addressable U.S. tumor hyperinsulinism population per year

> “While we believe the total addressable market may be larger, the immediately addressable incidence market for the combined indications causing tumor HI is estimated to be approximately 3,000 patients in the U.S. alone per year.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

> “While we believe the total addressable market may be larger, the immediately addressable incidence market for the combined indications causing tumor HI is estimated to be approximately 4,000 patients in the U.S. alone per year.”
> “We believe 60% of these patients are managed at the National Cancer Institutes and academic medical centers, which will be our primary focus at launch.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-4.1-3"></a>

#### Earlier company estimate of the total addressable U.S. tumor hyperinsulinism market including NICTH

> “The inclusion of NICTH patients in a potential addressable market for RZ358 in tumor HI would more than double the population.”
> “The total addressable market for the combined indications causing tumor HI is estimated to be approximately 4,500 patients in the U.S.”

Source: [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth)

<a id="topic-4.1-4"></a>

#### Claims-based count of addressable U.S. patients with malignant insulinoma and NICTH

| Field | Corporate presentation, October 2026 |
| --- | --- |
| Malignant insulinoma | “~2,500 Addressable Malignant Insulinoma Patients in the U.S.” |
| Malignant insulinoma claims definition | “ICD - 10 code C25.4 is for malignant neoplasm of the endocrine pancreas, or cancer of the endocrine pancreas” |
| Repeated hospitalization criterion | “inpatient or emergency department encounters with a hypoglycemia - related diagnosis” |
| NICTH | “~1,500 Addressable NICTH Patients in the U.S.” |
| NICTH claims definition | “Patients with qualifying tumor” |
| Measure | “Point - in - time prevalence as of Oct 2026.” |
| Data source | “Source: Veeva Compass database; covers more than 70% of US patients” |

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-4.1-5"></a>

#### Company payer research on pricing, utilization management, and reimbursement

> “Insulinoma and NICTH indications with a high unmet need and low budgetary impact, supporting ultra - rare disease pricing”
> “Expect to manage ersodetug with a prior authorization aligned to the label and a step - through diazoxide for patients with insulinoma”
> “Inclusion in NCCN and ENDO Society guidelines expedites the payer approval process”
> “Expect institutions, particularly NCI - designated centers, to be adept at navigating the medical exception process for payer approvals”
> “Reimbursement via J - code (buy and bill) simplifies the approval administration burden”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-4.1-6"></a>

#### Tumor hyperinsulinism payer mix in claims data

| Primary payer | Share of patients |
| --- | --- |
| Commercial | “43.9%” |
| Medicare | “48.6%” |
| Medicaid | “5.5%” |
| Other | “2.0%” |
| Assignment method | “Primary payer assigned from the most frequently observed claim dates.” |
| Other payers | “Other include VA, DoD, etc.” |

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-4.1-7"></a>

#### Weight-based dosing and vial use per patient in tumor hyperinsulinism

> “Tumor HI maintenance dose: 9 mg/kg”
> “Adult patient average weight: ~80 kg”
> “Patients will use 9 vials per infusion on average”
> “117 vials per year per patient assuming infusion every four weeks”
> “Payer research confirms likely acceptance of rare - disease weight - based pricing for both indications”
> “With weight - based dosing, tumor HI patients require ~3X more vials compared to congenital HI patients”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-4.1-8"></a>

#### Company market opportunity estimates for tumor hyperinsulinism and combined indications

> “Tumor HI: ~4,000 patients; $4 - 5B TAM”
> “Combined U.S. opportunity ~6,000 patients”
> “Total $5B+ global market opportunity with additional upside through expansion”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

> “The discussion focused on commercial outlook and launch strategy for ersodetug.”
> “Potential $5 billion combined market opportunity.”

Source: [Rezolute first quarter fiscal 2027 results release (2026)](https://ir.rezolutebio.com/news/detail/388/rezolute-reports-first-quarter-fiscal-2027-financial-results-and-provides-business-update)

<a id="topic-4.1-9"></a>

#### Published analyst sales forecasts for ersodetug in tumor hyperinsulinism

No evidence found.

<a id="topic-4.1-10"></a>

#### Health technology assessments and published economic evaluations of ersodetug

No evidence found.

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

##### Summary

No budget impact model for ersodetug in tumor hyperinsulinism has been published, and the manufacturer has published no price. The report holds the following inputs for one:

- Eligible population: the manufacturer's U.S. estimates of approximately 3,000 patients per year (Form 10-K) or approximately 4,000 patients per year (Form 10-Q) as the immediately addressable incidence market, approximately 4,500 patients as the total addressable market (2024 release), and about 2,500 malignant insulinoma and about 1,500 NICTH patients as a point-in-time prevalence as of October 2026 (October 2026 presentation). Each figure describes a different measure.
- Treatment setting: the manufacturer believes 60% of patients are managed at National Cancer Institutes and academic medical centers.
- Drug use: the studied regimen is 9 mg/kg weekly for 8 weeks, followed by extension dosing every 2 to 4 weeks. The manufacturer assumes about 80 kg average adult weight, 9 vials per infusion, and 117 vials per year per patient with infusion every four weeks.
- Payer mix: Medicare 48.6%, commercial 43.9%, Medicaid 5.5%, and other 2.0% of patients in the company's claims data.
- Price: no wholesale acquisition cost or average sales price exists for the investigational product. The manufacturer's payer research describes expected ultra-rare disease pricing and weight-based pricing with reimbursement through a J-code.

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm); [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
